elisabeth iljas heath, md - Division of Hematology/Oncology - Wayne ...

(Principal Investigator for KCI/WSU- Dr. Elisabeth Heath)6. A Phase II Trial of VEGF-TRAP in Patients with Advanced BladderCancer (approved, submitted to PRMC) (Collaboration with CaliforniaCancer Consortium, Study Principal Investigator: Dr. PrzemyslawTwardowski) (Principal Investigator for KCI/WSU- Dr. ElisabethHeath)7. A Randomized, Phase I Trial of Neoadjuvant Androgen Deprivation withand without GW786034 in Patients with High Risk Prostate CancerUndergoing Radical Prostatectomy (not approved) (Collaboration withCalifornia Cancer Consortium) (Principal Investigator-Dr. ElisabethHeath)8. Pilot Testing of VEGF/PDGF inhibitor AZD2171 for chemoprevention ofprostate cancer bone metastasis in preclinical models (approved)(Collaboration with Dr. Hyeong-Reh Kim, Ph.D., Wayne State University)(Co-Principal Investigator-Dr. Elisabeth Heath)CURRENT INDUSTRIAL GRANTS:1. Bristol-Myers Squibb (Contract # CA165002, Account # 420758)(Z-2770) A Phase I Safety, Pharmacokinetic, Dose-Escalation Study of BMS-275183 Administered as a Continuous Weekly Schedule in Patients with AdvancedSolid Tumors$ 112,200.00; 06/01/04-06/30/07PI: Elisabeth I. Heath, M.D.Role: Principal InvestigatorStatus: ActiveEffort: 5%2. Bristol-Myers Squibb(2834) A Phase I Study of BMS-275183 Given on a Daily Schedule in Patients withAdvanced Malignancies$ 223,600.00;09/24/04-07/05/07PI: Elisabeth I. Heath, M.D.Role: Principal InvestigatorStatus: ActiveEffort: 5%3. Pfizer(Z-2980) Phase I Study of SU011248 in Combination with Paclitaxel/Carboplatin inPatients with Advanced Solid Malignancies (Protocol # A96181037)$ 90,218; 09/15/05-09/14/08PI: Elisabeth I. Heath, M.D.12